|
2.11 Etiologie - Alimentation
|
|
|
|
2.7 Etiologie - Obésité
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
Drugmakers, Amazon Back Grail’s Big Cancer Trials With $900M [Xconomy]
|
|
|
|
|
|
Grail
needs the huge war chest to fund an exceedingly difficult quest. It is
conducting large, long trials to test the worth of a blood test meant to
catch cancer when it’s most treatable—long before patients show any
symptoms—by detecting fragments of cancer DNA shed by tumors.
|
|
|
|
|
|
|
|
|
5. Traitements
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy [Xconomy]
|
|
|
|
|
|
“Until
the picture is complete, it’s wrong to isolate any variable,” Bishop
said at the time. The picture still remains unclear. In a statement this
afternoon, Juno said it identified “multiple factors” that could have
contributed to the problem, from the chemotherapy to the product itself.
|
|
|
|
|
|
|
Juno pulls the plug on a once-promising cancer treatment [STAT]
|
|
|
|
|
|
DLBCL
is the most common form of non-Hodgkin lymphoma, and CAR-T therapies,
which would treat patients whose cancer endured standard treatment,
present a blockbuster opportunity. Kite’s DLBCL treatment is in line for
peak sales of $1.5 billion a year, according to Cowen analyst Eric
Schmidt.
|
|
|
|
|
|
|
|
|
5.2 Pharma
|
|
|
|
|
|
|
Roche says drug combo cuts breast cancer deaths in key trial [Reuters]
|
|
|
|
|
|
Roche
said on Thursday that combing its Perjeta and Herceptin drugs with
chemotherapy reduced recurrence of aggressive breast cancer or death
compared to Herceptin and chemo, an important trial outcome seen helping
shield the Swiss drugmaker's oncology franchise from cheaper copies.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
FDA Approves Nivolumab for Bladder Cancer [NCI]
|
|
|
|
|
|
This
study of nivolumab has some limitations, Dr. Apolo noted. For example,
because it was a single-arm study, the efficacy of nivolumab was not
compared directly with that of another treatment. In addition, the
accelerated approval was based on the objective response rate, the
study’s surrogate endpoint.
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
5.9 AACR
|
|
|
|
5.9.8 AACR - Pharma
|
|
|
|
|
|
6.1 Observation
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
6.11 Patients
|
|
|
|
6.3 Associations/Fondations
|
|
|
|